Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia

... development and commercialization of novel antibiotics for the treatment of antibiotic-resistant ... spectrum and improve the utility of this class of antibiotics relative to the only other oxazolidinone marketed ... synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ...

Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited

... - GBP13.1 Million Funding to Drive Novel antibiotics Platform Addressing Areas of Major Unmet Need, ... Partner of CP2 said: "The urgent need for new antibiotics is well known, Novacta represents a ... Tony Sedgwick, producing important new antibiotics and a great return for existing Novacta ...

Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors

... focused on the discovery and development of novel antibiotics for the treatment of antibiotic resistant ... synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ... engine has yielded several distinctive new antibiotics that can be used for the treatment of either ...

Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections

... antibiotics. Orally and parenterally administered antibiotics are often associated with systemic side effects ... (ischemia), which may render systemically acting antibiotics less effective. Infection can also spread to the ... tissue. Currently, there are no topically applied antibiotics marketed in the US that are specifically ...

Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

... focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant ... synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ... engine has yielded several distinctive new antibiotics that can be used for the treatment of either ...

Neogen Develops Quickest Single Test for Beta-Lactams and Tetracyclines in Milk

... "As the use of both tetracycline and beta-lactam antibiotics for the management of mastitis in dairy herds has ... test to simultaneously detect both groups of antibiotics has also grown," said Ed Bradley, Neogen's vice ... at the farm level. The tetracycline group of antibiotics is not as widely used as the beta-lactam group; ...

Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush

... that developed a portfolio of leading hospital antibiotics including levofloxacin (Levaquin), doripenem ... focused on the discovery and development of novel antibiotics designed to overcome the significant global ... The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are ...

MIT, BU team combats antibiotic resistance with engineered viruses

... to combat these superbugs, but very few new antibiotics have been developed in the past few decades. ... system enlisted when bacteria are exposed to antibiotics that damage DNA, and other gene networks. Used in ... tested their phages with three major classes of antibiotics (quinolones, beta-lactams and aminoglyclosides) ...

Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing

... focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant ... synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ... engine has yielded several distinctive new antibiotics that can be used for the treatment of either ...

Advanced Life Sciences Announces Third Quarter 2008 Financial Results

... emerging role in the large and growing global antibiotics market. We look forward to continuing this ... of $2 billion dollars for prescribed antibiotics to treat CAP. CAP is potentially fatal if not ... more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can ...

Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008

... HELSINKI, October 28 /PRNewswire/ -- Northern antibiotics Ltd., the developer of novel polymyxin ... 46th Annual Meeting in Washington, DC. Northern antibiotics has developed two series of novel polymyxin ... remarkable degree these Gram negative bacteria to antibiotics such as macrolides, rifampin, and others. The ...

Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting

... development and commercialization of novel antibiotics for the treatment of antibiotic-resistant ... synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ... engine has yielded several distinctive new antibiotics that can be used for the treatment of either ...

Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board

... focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant ... synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ... engine has yielded several distinctive new antibiotics that can be used for the treatment of either ...

GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections

... combine compounds with multiple new and existing antibiotics to create a broad offering of anti-infective ... stage compounds as well as existing commercial antibiotics to improve potency and broaden the spectrum ... used in combination with commercially available antibiotics and with proprietary GSK antibiotics. ...

Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection

... be added to the National Stockpile." Currently antibiotics represent the only option for the treatment of anthrax infection. antibiotics may be effective in killing the bacteria, but can ... effects of anthrax toxins. In addition, current antibiotics may not be effective at all against antibiotic ...

Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institute's 2nd Annual Challenge of Antibacterial Development Conference

... focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant ... Discovery to Define Novel Macrolide antibiotics Targeting the 50S Ribosomal Subunit," will focus ... synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to ...

Neogen Launches Quickest Test Available for Tetracyclines in Milk

... milk. The tetracyclines group of dairy antibiotics is used to treat bovine mastitis, and includes ... tetracyclines have emerged as a second choice of antibiotics to beta- lactams for the management of mastitis ... Two years ago when we acquired the dairy antibiotics business from UCB, including its popular BetaStar ...

Targanta Submits Oritavancin New Drug Application

... gram-positive strains resistant to commonly used antibiotics such as oxacillin, methicillin, vancomycin, ... "Despite the introduction of several new antibiotics in the past decade, we continue to see an ... Antibiotics There is a growing need for novel antibiotics since bacteria can mutate quickly and often ...

Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting

... of antibiotics to generate molecules that deliver antibiotics directly to the bone. The following abstracts ... antibiotics (AABs) Against ... on developing and commercializing innovative antibiotics to treat serious infections in the hospital and ...

Probiotic good bugs may control gut infections

... be an effective substitute for growth promoting antibiotics in pigs, giving us safer pork products, according ... Recently the European Union banned the use of antibiotics in animal feed. antibiotics were being regularly used as growth promoters to ...

NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

... entities may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of antibiotic-resistant bacterial ... to be effective against bacteria in biofilms, which render most antibiotics ineffective. Aganocides have a broad therapeutic index while providing a ...

DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies

... majority of known nucleic acid sequences. Half of all clinically used antibiotics target bacterial ribosomes, which are RNA-based molecules. Yet, the 3D ... target for structural prediction and future drug development, including antibiotics for pathogenic bacteria that have developed drug resistance. DNA ...

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

... Raxibacumab represents a new way to address the anthrax threat. While antibiotics can kill the anthrax bacteria, they are not effective against the deadly ... toxins already are circulating in their blood, and it may be too late for antibiotics alone to be effective. About the Raxibacumab Contract with the ...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

... Raxibacumab represents a new way to address the anthrax threat. While antibiotics can kill the anthrax bacteria, they are not effective against the deadly ... toxins already are circulating in their blood, and it may be too late for antibiotics alone to be effective. "We are very proud that the importance of ...

EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries

... a GMP-compliant formulation. The Company will market its beta-lactamase to antibiotics manufacturers to improve quality control, to the diagnostics industry, and ... of up to EUR 5 million. "The launch of a beta-lactamase for the antibiotics industry and other uses opens a new phase in the development of our ...

Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI

... cases, death. CDI typically develops from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, allowing C. difficile ... . About Fidaxomicin Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, ...

Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer

... formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria ... found in many gram-negative bacterial pathogens. Bacterial efflux of antibiotics is a leading source of multi-drug resistance, particularly in ...

NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions

... These compounds may deliver the same or better efficacy as currently used antibiotics without contributing to the growing rise of bacterial resistance. This ... to be effective against bacteria in biofilm, which render most antibiotics ineffective. The combined anti-bacterial and anti-fungal properties and ...

Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609

... at the NIH serves a vital role in assisting companies to develop new antibiotics for important infectious diseases that impact U.S. public health." ... therapy for such a long period of time. Decades of misuse of the existing antibiotics and poor compliance created an epidemic of drug resistance that now ...

Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results

... estimated total annual expenditure of $2.0 billion dollars for prescribed antibiotics to treat CAP. CAP is potentially fatal if not treated properly, and the ... has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging ...

Neogen's BetaStar(R) US Dairy Antibiotic Test Approved by FDA/NCIMS

... Milk Shipments (NCIMS) for its quick and easy BetaStar(R)US test for dairy antibiotics in milk. This approval allows milk producers and processors in the United ... Research Institute (AOAC-RI No. 030802) after rigorous testing. antibiotics have been used in cows for many years to treat such common infections as ...

Tips from the journals of the American Society for Microbiology

... strains found in breast milk may provide an alternative method to antibiotics for effectively treating mastitis, a common infection that occurs in ... agents associated with mastitis, increased multi-drug resistance to antibiotics are making such infections difficult to treat, therefore prompting ...

Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia

... an estimated total annual expenditure of $2 billion dollars for prescribed antibiotics to treat CAP. CAP is potentially fatal if not treated properly, and the ... has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging ...

Tips from the journals of the American Society for Microbiology

... strains found in breast milk may provide an alternative method to antibiotics for effectively treating mastitis, a common infection that occurs in ... agents associated with mastitis, increased multi-drug resistance to antibiotics are making such infections difficult to treat, therefore prompting ...

Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA

... class of antibiotics, the most frequently prescribed class of antibiotics in the world. Ceftaroline is also being studied in Phase III clinical ... in Dermatology. Jan 2007. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus ...

Tips from the journals of the American Society for Microbiology

... strains found in breast milk may provide an alternative method to antibiotics for effectively treating mastitis, a common infection that occurs in ... agents associated with mastitis, increased multi-drug resistance to antibiotics are making such infections difficult to treat, therefore prompting ...

MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China

... compound that we expect to be superior to many of the top- selling antibiotics available today," said Zhengyu Yuan, Ph.D., president and chief executive ... profile of clinically validated antibiotic classes, creating best-in-class antibiotics capable of addressing the growing problem of the bacterial multi-drug ...

Advanced Life Sciences Announces Second Quarter 2008 Financial Results

... an estimated total annual expenditure of $2 billion dollars for prescribed antibiotics to treat CAP. CAP is potentially fatal if not treated properly, and the ... has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging ...

FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia

... made by the FDA. "We recognize that there is an important need for new antibiotics to treat these serious hospital infections," said Joanne Waldstreicher, ... class of antibacterial drugs called carbapenems. Carbapenems are important antibiotics to treat serious -- and sometimes life-threatening -- infections caused by ...

Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP

... for injection, USP, and cefuroxime for injection, USP, two broad spectrum antibiotics for parenteral administration used to treat bacterial infections. Sagent's ... bulk package vials. According to IMS data, combined 2007 sales for the two antibiotics were $156 million. "We are excited to introduce these two broad-spectrum ...